Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06979154). This is a study registration, not published results. Lead sponsor: University of North Carolina, Chapel Hill. Recruitment status: TERMINATED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 6 participants (ACTUAL). Conditions: Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls. Interventions: DEVICE: tACS (aperiodic). Primary outcome measures: Safety Via the Presence of Any Serious AEs Related to Stimulation , Healthy controls: Day 1 through Follow-up 1 (Day 19). Antenatal depression participants: Day 1 through birth outcome assessment within 90 days after delivery, up to 17 weeks after Day 1.; Feasibility Via the Number of Participants Enrolled Relative to the Target Recruitment in Each Group , Baseline to end of recruitment period (12 months following recruitment start); Feasibility Via the Number of Participants Completing All Study Visits Within the Intervention Period , Baseline (up to 7 days before intervention Day 1) to Day 5 (end of five-day intervention); Tolerability Via the Number of Participants Rating Stimulation-related Sensations as 'High' , Day 1 to Day 5; Tolerability Via the Proportion of Participants Reporting Intolerance to Stimulation , Day 1 to Day 5; Safety Via Review of Birth Outcomes Within 90 Days of Birth in the Antenatal Depression Population , Healthy controls: Day 1 through Follow-up 1 (Day 19). Antenatal depression participants: Day 1 through birth outcome assessment within 90 days after delivery, up to 17 weeks after Day 1.. Brief summary: The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.